ArticleThe Journal of experimental medicine2007
Type I interferons produced by hematopoietic cells protect mice against lethal infection by mammalian reovirus.
Article in The Journal of experimental medicine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 82 citations in OpenAlex.
- A single mutation in an enteric virus alters tropism and sensitivity to microbiota.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Immunoglobulin A controls intestinal virus colonization to preserve immune homeostasis.Cell host & microbe · 2025Article
- Regulation of host/pathogen interactions in the gastrointestinal tract by type I and III interferons.Current opinion in immunology · 2024Review
- Indoleamine 2,3-dioxygenase 1 regulates cell permissivity to astrovirus infection.Mucosal immunology · 2023Article
- NK cells contribute to reovirus-induced IFN responses and loss of tolerance to dietary antigen.JCI insight · 2022Article
- Early Events in Reovirus Infection Influence Induction of Innate Immune Response.Journal of virology · 2022Article
- Reovirus Activated Cell Death Pathways.Cells · 2022Review
- Oncolytic virus treatment differentially affects the CD56Immunology · 2022Article
- Infection of non-cancer cells: A barrier or support for oncolytic virotherapy?Molecular therapy oncolytics · 2022Review
- DHX15 is required to control RNA virus-induced intestinal inflammation.Cell reports · 2021Article
- Lymphatic Type 1 Interferon Responses Are Critical for Control of Systemic Reovirus Dissemination.Journal of virology · 2021Article
- Article
- Past, Present and Future of Oncolytic Reovirus.Cancers · 2020Review
- Review
- Using Diverse Model Systems to Define Intestinal Epithelial Defenses to Enteric Viral Infections.Cell host & microbe · 2020Review
- Type III interferons: Balancing tissue tolerance and resistance to pathogen invasion.The Journal of experimental medicine · 2020Review
- Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Article
- Article
- Review
- Reovirus-Induced Apoptosis in the Intestine Limits Establishment of Enteric Infection.Journal of virology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
We defined the function of type I interferons (IFNs) in defense against reovirus strain type 1 Lang (T1L), which is a double-stranded RNA virus that infects Peyer's patches (PPs) after peroral inoculation of mice. T1L induced expression of mRNA for IFN-alpha, IFN-beta, and Mx-1 in PPs and caused localized intestinal infection that was cleared in 10 d. In contrast, T1L produced fatal systemic infection in IFNalphaR1 knockout (KO) mice with extensive cell loss in lymphoid tissues and necrosis of the intestinal mucosa. Studies of bone-marrow chimeric mice indicated an essential role for hematopoietic cells in IFN-dependent viral clearance. Dendritic cells (DCs), including conventional DCs (cDCs), were the major source of type I IFNs in PPs of reovirus-infected mice, whereas all cell types expressed the antiviral protein Mx-1. Neither NK cells nor signaling via Toll-like receptor 3 or MyD88 were essential for viral clearance. These data demonstrate a requirement for type I IFNs in the control of an intestinal viral infection and indicate that cDCs are a significant source of type I IFN production in vivo. Therefore, innate immunity in PPs is an essential component of host defense that limits systemic spread of pathogens that infect the intestinal mucosa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.